Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Findings from University of Washington provide new insights into life sciences
January 14th, 2009
"Frangakis and Rubin (2002, Biometrics 58, 21-29) proposed a new definition of a surrogate end-point (a ''principal'' surrogate) based on causal effects. We introduce an estimand for evaluating a principal surrogate, the causal effect predictiveness (CEP) surface, which quantifies how well causal treatment effects on the biomarker predict causal treatment effects on the clinical endpoint," scientists in the United States report. "Although the CEP surface is not identifiable due to missing potential outcomes, it can be identified by incorporating a baseline covariate(s) that predicts the biomarker. Given case-cohort sampling of such a baseline predictor and the biomarker...
Source: Vaccine Weekly (2009-01-14)
|
